|
| 36845293 | Novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of <i>Hoxa</i> cluster genes and promotion of neuronal lineage. | Neurooncol Adv | 2023 |
| 35994777 | National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. | Neuro Oncol | 2023 |
| 37818078 | ATXN3 deubiquitinates YAP1 to promote tumor growth. | | 2023 |
| 37415222 | Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. | J Transl Med | 2023 |
| 37219390 | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen. | CNS Oncol | 2023 |
| 36647828 | Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. | J Clin Invest | 2023 |
| 36534983 | Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. | Neuro Oncol | 2023 |
| 36849306 | Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products. | | 2023 |
| 37532182 | ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients. | Mod Pathol | 2023 |
| 35103816 | High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. | Acta Neuropathol | 2022 |
| 35460555 | Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. | Neuro Oncol | 2022 |
| 35395831 | A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. | Acta neuropathologica communications | 2022 |
| 36042143 | Off the Clock: the Non-canonical Roles of Cyclin-Dependent Kinases in Neural and Glioma Stem Cell Self-Renewal. | Molecular Neurobiology | 2022 |
| 35524725 | A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M. | GLIA | 2022 |
| 35902341 | Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. | Pract Radiat Oncol | 2022 |
| 36226717 | The 2021 WHO classification of central nervous system tumors: what neurologists need to know. | Current Opinion in Neurology | 2022 |
| 35878398 | Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. | Arch Pathol Lab Med | 2022 |
| 36274161 | Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. | Acta Neuropathol Commun | 2022 |
| 36067783 | An integrative web-based software tool for multi-dimensional pathology whole-slide image analytics. | Phys Med Biol | 2022 |
| 35859542 | Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. | Neurooncol Pract | 2022 |
| 35605901 | Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors. | J Mol Diagn | 2022 |
| 35039931 | Necrotic reshaping of the glioma microenvironment drives disease progression. | Acta Neuropathologica | 2022 |
| 35175291 | Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. | Arch Pathol Lab Med | 2022 |
| 35149861 | Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2022 |
| 35121903 | ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2021 |
| 34171600 | Solitary fibrous tumor of thoracic cavity, extra-thoracic sites and central nervous system: Clinicopathologic features and association with local recurrence and metastasis. | Pathol Res Pract | 2021 |
| 33692132 | A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. | Sci Transl Med | 2021 |
| 34250480 | Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. | Neurooncol Adv | 2021 |
| 34325467 | Hypoxia-inducible factors individually facilitate inflammatory myeloid metabolism and inefficient cardiac repair. | Journal of Experimental Medicine | 2021 |
| 34185076 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. | Neuro Oncol | 2021 |
| 34409295 | Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. | Neurooncol Adv | 2021 |
| 34777835 | Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. | Neurooncol Pract | 2021 |
| 34433651 | TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. | Clin Cancer Res | 2021 |
| 31219344 | Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. | Arch Pathol Lab Med | 2020 |
| 32324425 | The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2020 |
| 32134155 | Methods for in vitro modeling of glioma invasion: Choosing tools to meet the need. | GLIA | 2020 |
| 32307792 | cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. | Brain Pathol | 2020 |
| 31996992 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. | Acta Neuropathol | 2020 |
| 32346735 | Spinocerebellar Ataxia Type 3: A Case Report and Literature Review. | Journal of Neuropathology and Experimental Neurology | 2020 |
| 32217177 | Bone Flap Resorption Associated with Indolent Propionibacterium acnes Infection After Cranioplasty: Case Report with Pathological Analysis. | World Neurosurgery | 2020 |
| 32483596 | Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas? | J Neuropathol Exp Neurol | 2020 |
| 32445025 | The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. | Curr Neurol Neurosci Rep | 2020 |
| 32935128 | Epithelioid Pituicytoma: Expanding the Morphologic Spectrum of a Rare Neoplasm. | Journal of Neuropathology and Experimental Neurology | 2020 |
| 32537180 | Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. | Neurooncol Pract | 2020 |
| 32565902 | The recurrence of the melanotic neuroectodermal tumour of infancy: an unusual presentation of a rare tumour. | ecancermedicalscience | 2020 |
| 33222970 | Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. | J Clin Neurosci | 2020 |
| 33215342 | The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. | Journal of Neuro-Oncology | 2020 |
| 30830209 | What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW. | Journal of Neuropathology and Experimental Neurology | 2019 |
| 31748746 | Longitudinal molecular trajectories of diffuse glioma in adults. | Nature | 2019 |
| 31646100 | Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. | OncoImmunology | 2019 |